These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 32591969

  • 1. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
    Balram B, Lubov J, Theoret Y, Afif W, Bitton A, Wild G, Lakatos PL, Bessissow T.
    Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
    [Abstract] [Full Text] [Related]

  • 2. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, UK IBD BioResource Investigators, Raine T, Parkes M, UK IBD Bioresource Investigators.
    Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
    [Abstract] [Full Text] [Related]

  • 3. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
    Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JR, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW.
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1313-23. PubMed ID: 25284134
    [Abstract] [Full Text] [Related]

  • 4. 6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.
    Actis GC, Pellicano R, Rosina F.
    Inflamm Allergy Drug Targets; 2015 Dec; 14(2):133-7. PubMed ID: 26728773
    [Abstract] [Full Text] [Related]

  • 5. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
    Boyle BM, Kappelman MD, Colletti RB, Baldassano RN, Milov DE, Crandall WV.
    World J Gastroenterol; 2014 Jul 21; 20(27):9185-90. PubMed ID: 25083093
    [Abstract] [Full Text] [Related]

  • 6. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
    Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT.
    J Clin Gastroenterol; 2018 Jul 21; 52(6):537-544. PubMed ID: 28723860
    [Abstract] [Full Text] [Related]

  • 7. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
    Ranjan MK, Vuyyuru SK, Kante B, Kumar P, Mundhra SK, Golla R, Sharma R, Sahni P, Das P, Makharia G, Kedia S, Ahuja V.
    Int J Colorectal Dis; 2022 Aug 21; 37(8):1817-1826. PubMed ID: 35835862
    [Abstract] [Full Text] [Related]

  • 8. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
    Thapa SD, Hadid H, Usman M, Imam W, Hassan A, Schairer J, Jafri SM, Kaur N.
    Dig Dis Sci; 2016 Jan 21; 61(1):230-7. PubMed ID: 26511478
    [Abstract] [Full Text] [Related]

  • 9. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
    Hanauer SB, Sandborn WJ, Lichtenstein GR.
    Gastroenterology; 2019 Jan 21; 156(1):36-42. PubMed ID: 30195449
    [Abstract] [Full Text] [Related]

  • 10. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B, TOPIC Recruitment Team.
    Gastroenterology; 2015 Oct 21; 149(4):907-17.e7. PubMed ID: 26072396
    [Abstract] [Full Text] [Related]

  • 11. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
    Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P.
    Dig Dis Sci; 2019 Jun 21; 64(6):1612-1621. PubMed ID: 30604371
    [Abstract] [Full Text] [Related]

  • 12. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
    Ranjan MK, Kante B, Vuyyuru SK, Kumar P, Mundhra SK, Golla R, Sharma R, Sahni P, Das P, Makharia G, Kedia S, Ahuja V.
    J Gastroenterol Hepatol; 2022 Aug 21; 37(8):1544-1553. PubMed ID: 35501287
    [Abstract] [Full Text] [Related]

  • 13. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.
    Dig Dis Sci; 2018 Jun 21; 63(6):1583-1591. PubMed ID: 29564674
    [Abstract] [Full Text] [Related]

  • 14. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
    Alexakis C, Saxena S, Chhaya V, Cecil E, Curcin V, Pollok R.
    Inflamm Bowel Dis; 2017 Apr 21; 23(4):672-680. PubMed ID: 28151735
    [Abstract] [Full Text] [Related]

  • 15. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
    Akiyama S, Matsuoka K, Fukuda K, Hamada S, Shimizu M, Nanki K, Mizuno S, Kiyohara H, Arai M, Sugimoto S, Iwao Y, Ogata H, Hisamatsu T, Naganuma M, Motobayashi M, Suzuki K, Takenaka K, Fujii T, Saito E, Nagahori M, Ohtsuka K, Mochizuki M, Watanabe M, Hashiguchi M, Kanai T.
    J Gastroenterol Hepatol; 2019 Oct 21; 34(10):1751-1757. PubMed ID: 31045285
    [Abstract] [Full Text] [Related]

  • 16. Thiopurine-induced pancreatitis in inflammatory bowel diseases.
    Ledder O, Lemberg DA, Day AS.
    Expert Rev Gastroenterol Hepatol; 2015 Apr 21; 9(4):399-403. PubMed ID: 25494551
    [Abstract] [Full Text] [Related]

  • 17. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Apr 21; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

  • 18. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
    Thomsen SB, Allin KH, Burisch J, Jensen CB, Hansen S, Gluud LL, Theede K, Kiszka-Kanowitz M, Nielsen AM, Jess T.
    United European Gastroenterol J; 2020 Feb 21; 8(1):68-76. PubMed ID: 32213059
    [Abstract] [Full Text] [Related]

  • 19. Thiopurines in inflammatory bowel disease revisited.
    Bär F, Sina C, Fellermann K.
    World J Gastroenterol; 2013 Mar 21; 19(11):1699-706. PubMed ID: 23555158
    [Abstract] [Full Text] [Related]

  • 20. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, GETECCU study group.
    Aliment Pharmacol Ther; 2018 Oct 21; 48(8):839-851. PubMed ID: 30281832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.